Application and progress of circulating tumor DNA detection technology in the diagnosis and treatment of colorectal cancer

doi:10.3877/cma.j.issn.2095-3224.2023.06.003

Abstract

Abstract:

The incidence and mortality rate of colorectal cancer are in the forefront of malignant tumors, and problems such as the inability to diagnose colorectal cancer in an early stage and the recurrence after surgery have always plagued clinicians. In the era of precision medicine, liquid biopsy technology represented by circulating tumor DNA (ctDNA) has made great progress in many fields, such as early screening and diagnosis of colorectal cancer, detection of minimal residual disease, efficacy of adjuvant therapy and drug resistance monitoring. This review summarizes the recent progress in the diagnosis and treatment of colorectal cancer using the technology of ctDNA detection. Its future development is also discussed in this article.

Key words: Colorectal neoplasms, Circulating tumor DNA, Early diagnosis, Minimal residual disease, Efficacy prediction

Ruiqi Gu, Hongsheng Fang, Guoxiang Cai. Application and progress of circulating tumor DNA detection technology in the diagnosis and treatment of colorectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 453-459.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2023.06.003

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2023/V12/I06/453

References 60

[1]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021 [J]. CA Cancer J Clin, 2021, 71(1): 7-33.
[2]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[3]	Moghimi-Dehkordi B, Safaee A. An overview of colorectal cancer survival rates and prognosis in Asia [J]. World J Gastrointest Oncol, 2012, 4(4): 71-75.
[4]	Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer [J]. Nat Rev Clin Oncol, 2017, 14(9): 531-548.
[5]	林慧娴, 郑磊. 液体活检在肿瘤领域的研究进展[J]. 实用医学杂志, 2019, 35(10): 1685-1688.
[6]	吴一龙, 王长利, 孙燕, 等. 液体活检:规范与精准同行[J]. 循证医学, 2016, 16(4): 193-197.
[7]	Dasari A, Morris VK, Allegra CJ, et al. ctDNA applications and integration in colorectal cancer: an NCI colon and rectal-anal task forces whitepaper [J]. Nat Rev Clin Oncol, 2020, 17(12): 757-770.
[8]	Marcuello M, Vymetalkova V, Neves RPL, et al. Circulating biomarkers for early detection and clinical management of colorectal cancer [J]. Mol Aspects Med, 2019, 69: 107-122.
[9]	Zheng X, Xu K, Zhou B, et al. A circulating extracellular vesicles-based novel screening tool for colorectal cancer revealed by shotgun and data-independent acquisition mass spectrometry [J]. J Extracell Vesicles, 2020, 9(1): 1750202.
[10]	Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells [J]. Cancer Res, 2001, 61(4): 1659-1665.
[11]	Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA [J]. Cancer Discov, 2014, 4(6): 650-661.
[12]	Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications [J]. J Hematol Oncol, 2022, 15(1): 131.
[13]	Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies [J]. Sci Transl Med, 2014, 6(224): 224ra24.
[14]	Yang YC, Wang D, Jin L, et al. Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients [J]. Biosci Rep, 2018, 38(4): BSR20180322.
[15]	Xue J, Prabhakaran S, Prabhakaran S, et al. The utility of ctDNA in colorectal cancer with peritoneal metastases [J]. ANZ J Surg, 2023, 93(3): 506-509.
[16]	Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA [J]. Nat Rev Cancer, 2017, 17(4): 223-238.
[17]	Kerachian MA, Javadmanesh A, Azghandi M, et al. Crosstalk between DNA methylation and gene expression in colorectal cancer, a potential plasma biomarker for tracing this tumor [J]. Sci Rep, 2020, 10(1): 2813.
[18]	Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer [J]. Gut, 2014, 63(2): 317-325.
[19]	Gao JJ, Wang YW, Li Y, et al. Performance of circulating methylated Septin9 gene DNA in diagnosis and recurrence monitoring of colorectal cancer in Western China [J]. Clin Chim Acta, 2022, 537: 118-126.
[20]	Sun J, Fei F, Zhang M, et al. The role of (m)SEPT9 in screening, diagnosis, and recurrence monitoring of colorectal cancer [J]. BMC Cancer, 2019, 19(1): 450.
[21]	Luo H, Zhao Q, Wei W, et al. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer [J]. Sci Transl Med, 2020, 12(524): eaax7533.
[22]	Chang SC, Liew PL, Ansar M, et al. Hypermethylation and decreased expression of TMEM240 are potential early-onset biomarkers for colorectal cancer detection, poor prognosis, and early recurrence prediction [J]. Clin Epigenetics, 2020, 12(1): 67.
[23]	Young GP, Symonds EL, Nielsen HJ, et al. Evaluation of a panel of tumor-specific differentially-methylated DNA regions in IRF4, IKZF1 and BCAT1 for blood-based detection of colorectal cancer [J]. Clin Epigenetics, 2021, 13(1): 14.
[24]	NCCN. Clinical practice guidelines in oncology-colon cancer, Version 2. 2023[EB/OL]. URL
[25]	Jin S, Zhu D, Shao F, et al. Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy [J]. Proc Natl Acad Sci USA, 2021, 118(5): e2017421118.
[26]	Cai G, Cai M, Feng Z, et al. A multilocus blood-based assay targeting circulating tumor DNA methylation enables early detection and early relapse prediction of colorectal cancer[J]. Gastroenterology, 2021, 161(6): 2053-2056.e2.
[27]	Wu X, Zhang Y, Hu T, et al. A novel cell-free DNA methylation-based model improves the early detection of colorectal cancer [J]. Mol Oncol, 2021, 15(10): 2702-2714.
[28]	Mo S, Dai W, Wang H, et al. Early detection and prognosis prediction for colorectal cancer by circulating tumour DNA methylation haplotypes: A multicentre cohort study [J]. E Clinical Medicine, 2023, 55: 101717.
[29]	Malla M, Loree JM, Kasi PM, et al. Using circulating tumor DNA in colorectal cancer: Current and evolving practices [J]. J Clin Oncol, 2022, 40(24): 2846-2857.
[30]	Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer [J]. Clin Cancer Res, 2021, 27(20): 5586-5594.
[31]	Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer [J]. Sci Transl Med, 2016, 8(346): 346ra92.
[32]	Tie J, Cohen JD, Wang Y, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III Colon Cancer [J]. JAMA Oncol, 2019, 5(12): 1710-1717.
[33]	Tie J, Cohen JD, Wang Y, et al. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study [J]. Gut, 2019, 68(4): 663-671.
[34]	Tie J, Cohen JD, Lo SN, et al. Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies [J]. Int J Cancer, 2021, 148(4): 1014-1026.
[35]	Kotani D, Oki E, Nakamura Y, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer [J]. Nat Med, 2023, 29(1): 127-134.
[36]	Henriksen TV, Tarazona N, Frydendahl A, et al. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences [J]. Clin Cancer Res, 2022, 28(3): 507-517.
[37]	Mo S, Ye L, Wang D, et al. Early detection of molecular residual disease and risk stratification for stage I to III colorectal cancer via circulating tumor DNA methylation [J]. JAMA Oncol, 2023, 9(6): 770-778.
[38]	Reinert T, Henriksen TV, Christensen E, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer [J]. JAMA Oncol, 2019, 5(8): 1124-1131.
[39]	Costas-Chavarri A, Nandakumar G, Temin S, et al. Treatment of patients with early-stage colorectal cancer: ASCO resource-stratified guideline [J]. J Glob Oncol, 2019, 5: 1-19.
[40]	Tie J, Cohen JD, Lahouel K, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer [J]. N Engl J Med, 2022, 386(24): 2261-2272.
[41]	Taieb J, Taly V, Henriques J, et al. Prognostic value and relation with adjuvant treatment duration of ctDNA in stage III colon cancer: a post hoc analysis of the PRODIGE-GERCOR IDEA-France trial [J]. Clin Cancer Res, 2021, 27(20): 5638-5646.
[42]	Kotaka M, Shirasu H, Watanabe J, et al. Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan [J]. Journal of Clinical Oncology, 2022, 40(Suppl. 4): 9.
[43]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会（CSCO）结直肠癌诊疗指南2023 [M]. 北京: 人民卫生出版社, 2023.
[44]	熊宇婷, 包雯. 伴随诊断新趋势：基于NGS的液体活检 [N]. 2020-12-15.
[45]	Willis J, Lefterova MI, Artyomenko A, et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel[J]. Clin Cancer Res, 2019, 25(23): 7035-7045.
[46]	Corcoran RB, Chabner BA. Application of cell-free DNA analysis to cancer treatment [J]. N Engl J Med, 2018, 379(18): 1754-1765.
[47]	Wang DS, Yang H, Liu XY, et al. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases [J]. Theranostics, 2021, 11(14): 7018-7028.
[48]	Tie J, Kinde I, Wang Y, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer [J]. Ann Oncol, 2015, 26(8): 1715-1722.
[49]	Garlan F, Laurent-Puig P, Sefrioui D, et al. Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients(PLACOL Study) [J]. Clin Cancer Res, 2017, 23(18): 5416-5425.
[50]	Kitahara M, Hazama S, Tsunedomi R, et al. Prediction of the efficacy of immunotherapy by measuring the integrity of cell-free DNA in plasma in colorectal cancer [J]. Cancer Sci, 2016, 107(12): 1825-1829.
[51]	Boland CR, Goel A. Microsatellite instability in colorectal cancer [J]. Gastroenterology, 2010, 138(6): 2073-2087.e3.
[52]	Wang C, Chevalier D, Saluja J, et al. Regorafenib and nivolumab or pembrolizumab combination and circulating tumor DNA response assessment in refractory microsatellite stable colorectal cancer [J]. Oncologist, 2020, 25(8): e1188-e1194.
[53]	Wang Z, Zhao X, Gao C, et al. Plasma-based microsatellite instability detection strategy to guide immune checkpoint blockade treatment [J]. J Immunother Cancer, 2020, 8(2): e001297.
[54]	Ciardiello F, Ciardiello D, Martini G, et al. Clinical management of metastatic colorectal cancer in the era of precision medicine [J]. CA Cancer J Clin, 2022, 72(4): 372-401.
[55]	Van Helden EJ, Angus L, Menke-Van Der Houven Van Oordt CW, et al. RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer [J]. Mol Oncol, 2019, 13(11): 2361-2374.
[56]	Cremolini C, Rossini D, Dell'aquila E, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: A phase 2 single-arm clinical trial [J]. JAMA Oncol, 2019, 5(3): 343-350.
[57]	Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer [J]. Nature, 2012, 486(7404): 532-536.
[58]	Khan KH, Cunningham D, Werner B, et al. Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C Phase II colorectal cancer clinical trial [J]. Cancer Discov, 2018, 8(10): 1270-1285.
[59]	Sartore-Bianchi A, Pietrantonio F, Lonardi S, et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial [J]. Nat Med, 2022, 28(8): 1612-1618.
[60]	Nakamura Y, Okamoto W, Kato T, et al. Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial [J]. Nat Med, 2021, 27(11): 1899-1903.

Please choose a citation manager

Content to export